L3VLUP
ProSign in

SYK · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

SYKLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • SYK
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterSYKLLY
Q3 202019 holders, $10.7bn33 holders, $14.1bn
Q4 202015 holders, $13.5bn29 holders, $17.3bn
Q1 202121 holders, $14.0bn24 holders, $23.0bn
Q2 202120 holders, $15.4bn24 holders, $27.8bn
Q3 202120 holders, $15.9bn31 holders, $29.9bn
Q4 202122 holders, $15.9bn31 holders, $34.7bn
Q1 202221 holders, $16.1bn24 holders, $35.3bn
Q2 202221 holders, $11.4bn33 holders, $42.7bn
Q3 202214 holders, $12.1bn31 holders, $43.4bn
Q4 202215 holders, $14.5bn31 holders, $46.6bn
Q1 202317 holders, $17.5bn33 holders, $44.3bn
Q2 202323 holders, $16.9bn37 holders, $59.6bn
Q3 202321 holders, $14.0bn44 holders, $67.6bn
Q4 202322 holders, $14.9bn45 holders, $73.6bn
Q1 202424 holders, $16.9bn41 holders, $95.3bn
Q2 202423 holders, $15.3bn43 holders, $110bn
Q3 202420 holders, $15.5bn45 holders, $107bn
Q4 202421 holders, $14.8bn46 holders, $93.9bn
Q1 202518 holders, $14.8bn42 holders, $98.4bn
Q2 202521 holders, $16.8bn43 holders, $93.2bn
Q3 202523 holders, $15.1bn39 holders, $86.7bn
Q4 202525 holders, $14.0bn41 holders, $123bn
Q1 202629 holders, $14.0bn39 holders, $106bn
Q2 202618 holders, $11.4bn44 holders, $132bn
SYK

Stryker Corporation

Holders
18
Reported value
$11.4bn
Buyers
16
Sellers
24

Breadth -8 among 91 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
LLY

Eli Lilly & Co

Holders
44
Reported value
$132bn
Buyers
24
Sellers
24

Breadth 0 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2026

Among the 47 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only SYK (3)

Davidson Kempner Capital Management LP, Point72 Asset Management LP, Winton Group Ltd

Only LLY (29)

ARK Investment Management LLC, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital World Investors, Citadel Advisors LLC, D. E. Shaw & Co., Discovery Capital Management LLC, Dodge & Cox, ExodusPoint Capital Management LP, Fidelity (FMR LLC), Freestone Grove Partners LP, Glenview Capital Management LLC, Harris Associates LP, Holocene Advisors LP, Hudson Bay Capital Management LP, Jane Street Group LLC, Man Group PLC, Marshall Wace LLP, Millennium Management LLC, Polen Capital Management LLC, Quantbot Technologies LP, Soros Fund Management LLC, Squarepoint Ops LLC, Susquehanna International Group LLP, and 4 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →